Former “String Of Pearls” Strategist Tabbed To Lead Teva’s Continuing Diversification
This article was originally published in The Pink Sheet Daily
Jeremy Levin, who left Bristol-Myers Squibb on Jan. 1, will succeed outgoing Teva CEO Shlomo Yanai in May, as the Israeli generics giant seeks to increase its emphasis on branded drugs.
You may also be interested in...
Teva’s new CEO, Jeremy Levin, has been emphasizing manufacturing efficiency, global compliance and a more focused R&D structure in initial comments to Wall Street.
Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.